<DOC>
	<DOCNO>NCT01138618</DOCNO>
	<brief_summary>Clozapine remain drug choice treatment resistant schizophrenia 60 % patient respond antipsychotic respond clozapine . However , use clozapine restrict due risk agranulocytosis consequently need mandatory hematological monitoring . CHEMPAQ XBC point-of-care device use patient home analyze WBC granulocyte single capillary blood drop . This study aim investigate whether new procedure increase acceptability clozapine</brief_summary>
	<brief_title>Hematological Clozapine Monitoring With Point-of-care Device ( CHEMPAQ )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<criteria>Treated clozapine Compliant blood monitoring Willing give inform consent Prior case agranulocytosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Clozapine</keyword>
	<keyword>hematological monitoring</keyword>
	<keyword>CHEMPAQ</keyword>
	<keyword>Granulocytes</keyword>
	<keyword>WBC</keyword>
</DOC>